Key Takeaways J&J projects stronger Innovative Medicine sales in H2 despite Stelara's LOE.Higher demand for Darzalex, Tremfya, and Erleada likely supported segment growth in Q3.Stelara biosimilars and IRA's Part D redesign continue to put pressure on J&J's drug sales.Johnson & Johnson (JNJ) , through its Innovative Medicine division, markets several blockbuster drugs across diverse therapeutic areas, including neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH), an ...